Fundraisings and IPOs

* On March 25, 2013, Serodus has announces that it has raised NOK 4.050.000 in gross proceeds through an

offering of 1.500.000 new shares at a subscription price of NOK 2.7 per share at a par value of NOK 1.3 per share. The shares to be issued upon the completion of the offering will represent approximately 14% of the current outstanding share capital of the Company. The offering was over-subscribed. The new shares issued in the offering are expected to be listed on Oslo Axess on or about 9 April 2013.

* On March 8, 2013, the board of directors of Serodus has announced that it has resolved to offer between 4,000 and 1,500,000 New Shares with the aim of raising gross proceeds of up to NOK 4,500,000 in the Initial Public Offering to be completed in connection with the listing of the Company\'s shares on Oslo Axess. The subscription price has been set at NOK 3.00 per share. In addition a 10 % cash discount to the Offer Price will apply for shareholders who subscribe for minimum 4,000 and maximum 8,000 Offer Shares. Trading of the shares on Oslo Axess is expected to commence on or about 4 April 2013 under the symbol \"SER\"

Serodus is focused on cardiovascular diseases and possesses two main products, the first-in-class compound SER100 and SER120. SER100 specifically targets isolated systolichypertension (ISH) – a subtype of arterial hypertension (AH), which is a prevalent form of AH in elderly. This opioid-1 (ORL1, nociceptin receptor) partial agonist was acquired from Zealand Pharma A/S in 2010. The data obtained from the studies with SER100 has so far shown a unique ability to decrease systolic blood pressure, while having aminimal effect on diastolic blood pressure. Results of  a proof?of?concept study (phase IIa) are expected early next year. The compound has already been tested in two separate clinical trials with heart failure patients.